GLYC
vs
S&P 500
GLYC
S&P 500
Over the past 12 months, GLYC has underperformed S&P 500, delivering a return of -36% compared to the S&P 500's +15% growth.
Stocks Performance
GLYC vs S&P 500
Performance Gap
GLYC vs S&P 500
Performance By Year
GLYC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GlycoMimetics Inc
Glance View
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 52 full-time employees. The company went IPO on 2014-01-10. The company is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. The company is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. The company has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The company has designed various small-molecule glycomimetic antagonists of galectin-3, including a product candidate that has demonstrated oral bioavailability.
